top of page

Biopharma grabs 55 new approvals in 2021

Writer's picture: Laurent DECORYLaurent DECORY

2020 and 2021 have definitely been Covid years ! Despite that, the Biopharma industry has been able to grab new 55 approvals in 2021, from molecular entities, biologics or cell therapies.


Among the most talked about are BioNTech/Pfizer Corminaty Covid-19 vaccine or Biogen's controversial Alzheimer drug Aduhelm.


This performance shows impressive resilience from the industry. Now, getting the most of those launches through omnichannel go-to-market and launch excellence is the critical next step.


This is where BlueJet Consulting can help !





Recent Posts

See All

コメント


bottom of page